ACADIA Pharmaceuticals Announces Results From Phase III Trial Of Pimavanserin In Parkinson's Disease Psychosis
Links shared publicly online about this topic.
- 1,778total visits
ACADIA Pharmaceuticals Announces Results From Phase III Trial Of Pimavanserin In Parkinson's Disease Psychosis
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced top-line results from the first pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis, or PDP. The study did
View full resource at medicalnewstoday.com
Tags: Parkinson's Disease, Disease and Condition, Pharma
Most Recently Shared on September 2, 2009 at 5:15 pm By:
ACADIA Pharmaceuticals Announces Results From Phase III Trial Of Pimavanserin In Parkinson's Disease Psychosis: .. http://bit.ly/jQIUV
Biovail Announces Results from ACADIA--™s Phase III Trial of Pimavanserin in Parkinson--™s Disease Psychosis | PD Online Research
pdonlineresearch.org — “Biovail Announces Results from ACADIA--™s Phase III Trial of Pimavanserin in Parkinson--™s Disease Psychosis | PD Online Research” View full resource at pdonlineresearch.org
Most Recently Shared on September 1, 2009 at 12:23 pm By:
PD Online Research Health Organization
Phase III trial results for treatment of Parkinson's Disease Psychosishttp://tinyurl.com/nhk9qs
Advertisement
